Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase II/III
Latest Information Update: 07 May 2018
At a glance
- Drugs Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 18 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 18 Dec 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.